CareDx, Inc (CDNA)

NASDAQ: CDNA · Real-Time Price · USD
19.11
+0.23 (1.22%)
Jun 25, 2025, 4:00 PM - Market closed
1.22%
Market Cap 1.06B
Revenue (ttm) 346.42M
Net Income (ttm) 62.08M
Shares Out 55.68M
EPS (ttm) 1.07
PE Ratio 17.78
Forward PE 26.31
Dividend n/a
Ex-Dividend Date n/a
Volume 614,446
Open 18.94
Previous Close 18.88
Day's Range 18.64 - 19.14
52-Week Range 13.81 - 34.84
Beta 2.18
Analysts Buy
Price Target 30.33 (+58.71%)
Earnings Date Jul 30, 2025

About CDNA

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ... [Read more]

Sector Healthcare
IPO Date Jul 17, 2014
Employees 650
Stock Exchange NASDAQ
Ticker Symbol CDNA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $30.33, which is an increase of 58.71% from the latest price.

Price Target
$30.33
(58.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead

CareDx has a unique, comprehensive organ transplant diagnostics portfolio and maintains strong revenue growth, but faces intensifying competition and regulatory risks. Recent legal resolutions and ope...

11 days ago - Seeking Alpha

CareDx Announces Repurchase of 5% of Outstanding Shares

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinica...

22 days ago - Business Wire

CareDx to Participate in Upcoming Investor Conferences

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

6 weeks ago - Business Wire

CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President & Chief Executive Officer Robert ...

2 months ago - Seeking Alpha

CareDx Reports First Quarter 2025 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter re...

2 months ago - Business Wire

CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

2 months ago - Business Wire

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

2 months ago - Business Wire

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ (“CareDx” or the “Company”)— a leading precision medicine company focused on the discovery, development, and co...

2 months ago - Business Wire

CareDx to Report First Quarter 2025 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...

2 months ago - Business Wire

CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its...

3 months ago - Business Wire

CI Global Asset Management Announces Securityholder Approval of Fund Mergers

TORONTO--(BUSINESS WIRE)---- $CDNA #CIFinancial--CI Global Asset Management has received securityholder approval to proceed with the merger of six mutual funds and two ETFs into other mandates.

3 months ago - Business Wire

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

NEW YORK and NEW ORLEANS , March 14, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

3 months ago - PRNewsWire

CareDx Launches Two Expanded Indications for AlloSure Testing Services

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

3 months ago - Business Wire

CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript

CareDx, Inc (NASDAQ:CDNA) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Ab...

4 months ago - Seeking Alpha

CareDx Announces Fourth Quarter and Full Year 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenu...

4 months ago - Business Wire

CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...

4 months ago - Business Wire

CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

4 months ago - Business Wire

CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

4 months ago - Business Wire

CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcar...

4 months ago - Business Wire

Final Trades: NRG Energy, MP Materials, CareDx and Applovin

The Investment Committee give you their top stocks to watch for the second half.

Other symbols: APPMPNRG
4 months ago - CNBC Television

CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 3...

5 months ago - Business Wire

CareDx: Top Of My Shopping List For 2025

CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown st...

6 months ago - Seeking Alpha

CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

6 months ago - Business Wire

TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

EDINBURGH, Scotland , Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...

7 months ago - PRNewsWire

CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinical...

7 months ago - Business Wire